{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T07:31:45Z","timestamp":1792654305368,"version":"4.5.0"},"reference-count":38,"publisher":"National Academy of Sciences","issue":"9","license":[{"start":{"date-parts":[[2017,8,13]],"date-time":"2017-08-13T00:00:00Z","timestamp":1502582400000},"content-version":"vor","delay-in-days":181,"URL":"http:\/\/www.pnas.org\/site\/misc\/userlicense.xhtml"}],"funder":[{"DOI":"10.13039\/100000002","name":"HHS | National Institutes of Health","doi-asserted-by":"publisher","award":["U19AI090023"],"award-info":[{"award-number":["U19AI090023"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"HHS | National Institutes of Health","doi-asserted-by":"publisher","award":["U19AI057266"],"award-info":[{"award-number":["U19AI057266"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.pnas.org"],"crossmark-restriction":true},"short-container-title":["Proc. Natl. Acad. Sci. U.S.A."],"published-print":{"date-parts":[[2017,2,28]]},"abstract":"<jats:title>Significance<\/jats:title>\n                  <jats:p>The RTS,S malaria vaccine is the most advanced malaria vaccine candidate to be tested in humans. Despite its promise, there is little understanding of its mechanism of action. In this work, we describe the use of a systems biological approach to identify \u201cmolecular signatures\u201d that are induced rapidly after the standard RTS,S vaccination regimen, consisting of three RTS,S immunizations, or with a different regimen consisting of a primary immunization with recombinant adenovirus 35 (Ad35) expressing the circumsporozoite malaria antigen followed by two immunizations with RTS,S. These results reveal important insights about the innate and adaptive responses to vaccination and identify signatures of protective immunity against malaria.<\/jats:p>","DOI":"10.1073\/pnas.1621489114","type":"journal-article","created":{"date-parts":[[2017,2,13]],"date-time":"2017-02-13T21:00:27Z","timestamp":1487019627000},"page":"2425-2430","update-policy":"https:\/\/doi.org\/10.1073\/pnas.cm10313","source":"Crossref","is-referenced-by-count":278,"title":["Systems analysis of protective immune responses to RTS,S malaria vaccination in humans"],"prefix":"10.1073","volume":"114","author":[{"given":"Dmitri","family":"Kazmin","sequence":"first","affiliation":[{"name":"Emory Vaccine Center, Emory University, Atlanta, GA 30329;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helder I.","family":"Nakaya","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, University of Sao Paulo, S\u00e3o Paulo 05508, Brazil;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva K.","family":"Lee","sequence":"additional","affiliation":[{"name":"School of Industrial and Systems Engineering, Georgia Institute of Technology, Atlanta, GA 30332;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Center for Genome Engineering, University of Minnesota, Minneapolis, MN 55108;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robbert","family":"van der Most","sequence":"additional","affiliation":[{"name":"GSK Vaccines, Rixensart 1330, Belgium;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"van den Berg","sequence":"additional","affiliation":[{"name":"GSK Vaccines, Rockville, MD 20850;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Ripley","family":"Ballou","sequence":"additional","affiliation":[{"name":"GSK Vaccines, Rockville, MD 20850;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Jongert","sequence":"additional","affiliation":[{"name":"GSK Vaccines, Rixensart 1330, Belgium;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Wille-Reece","sequence":"additional","affiliation":[{"name":"Program for Appropriate Technology in Health-Malaria Vaccine Initiative, Washington, DC 20001;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Ockenhouse","sequence":"additional","affiliation":[{"name":"Program for Appropriate Technology in Health-Malaria Vaccine Initiative, Washington, DC 20001;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Aderem","sequence":"additional","affiliation":[{"name":"Center for Infectious Disease Research, Seattle, WA 98109;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Zak","sequence":"additional","affiliation":[{"name":"Center for Infectious Disease Research, Seattle, WA 98109;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerald","family":"Sadoff","sequence":"additional","affiliation":[{"name":"Crucell, Leiden 2333, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Hendriks","sequence":"additional","affiliation":[{"name":"Crucell, Leiden 2333, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Wrammert","sequence":"additional","affiliation":[{"name":"Emory Vaccine Center, Emory University, Atlanta, GA 30329;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafi","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Emory Vaccine Center, Emory University, Atlanta, GA 30329;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bali","family":"Pulendran","sequence":"additional","affiliation":[{"name":"Emory Vaccine Center, Emory University, Atlanta, GA 30329;"},{"name":"Department of Pathology, Emory University School of Medicine, Atlanta, GA 30322"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"341","published-online":{"date-parts":[[2017,2,13]]},"reference":[{"key":"e_1_3_4_1_2","unstructured":"; World Health Organization World Malaria Report (World Health Organization Geneva). (2015)."},{"key":"e_1_3_4_2_2","first-page":"681","article-title":"Meeting of the Strategic Advisory Group of Experts on immunization, October 2015 - conclusions and recommendations","volume":"90","author":"Strategic Advisory Group of Experts","year":"2011","unstructured":"; Strategic Advisory Group of Experts, Meeting of the Strategic Advisory Group of Experts on immunization, October 2015 - conclusions and recommendations. Wkly Epidemiol Rec 90, 681\u2013699 (2011).","journal-title":"Wkly Epidemiol Rec"},{"key":"e_1_3_4_3_2","doi-asserted-by":"crossref","first-page":"90","DOI":"10.4161\/hv.6.1.9677","article-title":"From the circumsporozoite protein to the RTS, S\/AS candidate vaccine","volume":"6","author":"Cohen J","year":"2010","unstructured":"J Cohen, V Nussenzweig, R Nussenzweig, J Vekemans, A Leach, From the circumsporozoite protein to the RTS, S\/AS candidate vaccine. Hum Vaccin 6, 90\u201396 (2010).","journal-title":"Hum Vaccin"},{"key":"e_1_3_4_4_2","doi-asserted-by":"crossref","first-page":"4880","DOI":"10.1016\/j.vaccine.2010.05.033","article-title":"The RTS,S malaria vaccine","volume":"28","author":"Casares S","year":"2010","unstructured":"S Casares, TD Brumeanu, TL Richie, The RTS,S malaria vaccine. Vaccine 28, 4880\u20134894 (2010).","journal-title":"Vaccine"},{"key":"e_1_3_4_5_2","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.4049\/jimmunol.1400948","article-title":"Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells","volume":"193","author":"Didierlaurent AM","year":"2014","unstructured":"AM Didierlaurent, , Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells. J Immunol 193, 1920\u20131930 (2014).","journal-title":"J Immunol"},{"key":"e_1_3_4_6_2","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1093\/infdis\/171.6.1576","article-title":"Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine","volume":"171","author":"Gordon DM","year":"1995","unstructured":"DM Gordon, , Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J Infect Dis 171, 1576\u20131585 (1995).","journal-title":"J Infect Dis"},{"key":"e_1_3_4_7_2","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1086\/600120","article-title":"Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S\/AS01B and RTS,S\/AS02A in malaria-naive adults: Safety, efficacy, and immunologic associates of protection","volume":"200","author":"Kester KE","year":"2009","unstructured":"KE Kester, , Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S\/AS01B and RTS,S\/AS02A in malaria-naive adults: Safety, efficacy, and immunologic associates of protection. J Infect Dis; RTS,S Vaccine Evaluation Group 200, 337\u2013346 (2009).","journal-title":"J Infect Dis"},{"key":"e_1_3_4_8_2","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.2217\/fmb.15.90","article-title":"Clinical development of RTS,S\/AS malaria vaccine: A systematic review of clinical Phase I-III trials","volume":"10","author":"Agnandji ST","year":"2015","unstructured":"ST Agnandji, JF Fernandes, EB Bache, M Ramharter, Clinical development of RTS,S\/AS malaria vaccine: A systematic review of clinical Phase I-III trials. Future Microbiol 10, 1553\u20131578 (2015).","journal-title":"Future Microbiol"},{"key":"e_1_3_4_9_2","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(01)06957-4","article-title":"Efficacy of RTS,S\/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: A randomised trial","volume":"358","author":"Bojang KA","year":"2001","unstructured":"KA Bojang, , Efficacy of RTS,S\/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: A randomised trial. Lancet; RTS, S Malaria Vaccine Trial Team 358, 1927\u20131934 (2001).","journal-title":"Lancet"},{"key":"e_1_3_4_10_2","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/S0140-6736(04)17223-1","article-title":"Efficacy of the RTS,S\/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: Randomised controlled trial","volume":"364","author":"Alonso PL","year":"2004","unstructured":"PL Alonso, , Efficacy of the RTS,S\/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: Randomised controlled trial. Lancet 364, 1411\u20131420 (2004).","journal-title":"Lancet"},{"key":"e_1_3_4_11_2","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa0807381","article-title":"Efficacy of RTS,S\/AS01E vaccine against malaria in children 5 to 17 months of age","volume":"359","author":"Bejon P","year":"2008","unstructured":"P Bejon, , Efficacy of RTS,S\/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med 359, 2521\u20132532 (2008).","journal-title":"N Engl J Med"},{"key":"e_1_3_4_12_2","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S0140-6736(07)61542-6","article-title":"Safety of the RTS,S\/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: A double blind randomised controlled phase I\/IIb trial","volume":"370","author":"Aponte JJ","year":"2007","unstructured":"JJ Aponte, , Safety of the RTS,S\/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: A double blind randomised controlled phase I\/IIb trial. Lancet 370, 1543\u20131551 (2007).","journal-title":"Lancet"},{"key":"e_1_3_4_13_2","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1056\/NEJMoa0807773","article-title":"Safety and immunogenicity of RTS,S\/AS02D malaria vaccine in infants","volume":"359","author":"Abdulla S","year":"2008","unstructured":"S Abdulla, , Safety and immunogenicity of RTS,S\/AS02D malaria vaccine in infants. N Engl J Med 359, 2533\u20132544 (2008).","journal-title":"N Engl J Med"},{"key":"e_1_3_4_14_2","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1056\/NEJMoa1102287","article-title":"First results of phase 3 trial of RTS,S\/AS01 malaria vaccine in African children","volume":"365","author":"Agnandji ST","year":"2011","unstructured":"ST Agnandji, , First results of phase 3 trial of RTS,S\/AS01 malaria vaccine in African children. N Engl J Med; RTS,S Clinical Trials Partnership 365, 1863\u20131875 (2011).","journal-title":"N Engl J Med"},{"key":"e_1_3_4_15_2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","article-title":"Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: Final results of a phase 3, individually randomised, controlled trial","volume":"386","author":"The RTS,S Clinical Trial Partnership","year":"2015","unstructured":"; The RTS,S Clinical Trial Partnership, Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: Final results of a phase 3, individually randomised, controlled trial. Lancet 386, 31\u201345 (2015).","journal-title":"Lancet"},{"key":"e_1_3_4_16_2","doi-asserted-by":"crossref","first-page":"e1001685","DOI":"10.1371\/journal.pmed.1001685","article-title":"Efficacy and safety of the RTS,S\/AS01 malaria vaccine during 18 months after vaccination: A phase 3 randomized, controlled trial in children and young infants at 11 African sites","volume":"11","author":"RTS,S Clinical Trials Partnership","year":"2014","unstructured":"; RTS,S Clinical Trials Partnership, Efficacy and safety of the RTS,S\/AS01 malaria vaccine during 18 months after vaccination: A phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med 11, e1001685 (2014).","journal-title":"PLoS Med"},{"key":"e_1_3_4_17_2","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1056\/NEJMoa1208394","article-title":"A phase 3 trial of RTS,S\/AS01 malaria vaccine in African infants","volume":"367","author":"Agnandji ST","year":"2012","unstructured":"ST Agnandji, , A phase 3 trial of RTS,S\/AS01 malaria vaccine in African infants. N Engl J Med; RTS,S Clinical Trials Partnership 367, 2284\u20132295 (2012).","journal-title":"N Engl J Med"},{"key":"e_1_3_4_18_2","doi-asserted-by":"crossref","first-page":"e0131571","DOI":"10.1371\/journal.pone.0131571","article-title":"Ad35.CS.01-RTS,S\/AS01 heterologous prime boost vaccine efficacy against sporozoite challenge in healthy malaria-na\u00efve adults","volume":"10","author":"Ockenhouse CF","year":"2015","unstructured":"CF Ockenhouse, , Ad35.CS.01-RTS,S\/AS01 heterologous prime boost vaccine efficacy against sporozoite challenge in healthy malaria-na\u00efve adults. PLoS One 10, e0131571 (2015).","journal-title":"PLoS One"},{"key":"e_1_3_4_19_2","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1126\/science.1211548","article-title":"Live attenuated malaria vaccine designed to protect through hepatic CD8+ T cell immunity","volume":"334","author":"Epstein JE","year":"2011","unstructured":"JE Epstein, , Live attenuated malaria vaccine designed to protect through hepatic CD8+ T cell immunity. Science 334, 475\u2013480 (2011).","journal-title":"Science"},{"key":"e_1_3_4_20_2","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/nm.1991","article-title":"Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans","volume":"15","author":"O\u2019Brien KL","year":"2009","unstructured":"KL O\u2019Brien, , Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans. Nat Med 15, 873\u2013875 (2009).","journal-title":"Nat Med"},{"key":"e_1_3_4_21_2","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1128\/IAI.01879-06","article-title":"Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S\/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone","volume":"75","author":"Stewart VA","year":"2007","unstructured":"VA Stewart, , Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S\/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone. Infect Immun 75, 2283\u20132290 (2007).","journal-title":"Infect Immun"},{"key":"e_1_3_4_22_2","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.immuni.2010.10.006","article-title":"Systems vaccinology","volume":"33","author":"Pulendran B","year":"2010","unstructured":"B Pulendran, S Li, HI Nakaya, Systems vaccinology. Immunity 33, 516\u2013529 (2010).","journal-title":"Immunity"},{"key":"e_1_3_4_23_2","doi-asserted-by":"crossref","first-page":"12300","DOI":"10.1073\/pnas.1400476111","article-title":"Systems vaccinology: Probing humanity\u2019s diverse immune systems with vaccines","volume":"111","author":"Pulendran B","year":"2014","unstructured":"B Pulendran, Systems vaccinology: Probing humanity\u2019s diverse immune systems with vaccines. Proc Natl Acad Sci USA 111, 12300\u201312306 (2014).","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_4_24_2","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/ni.1688","article-title":"Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans","volume":"10","author":"Querec TD","year":"2009","unstructured":"TD Querec, , Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 10, 116\u2013125 (2009).","journal-title":"Nat Immunol"},{"key":"e_1_3_4_25_2","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/ni.2067","article-title":"Systems biology of vaccination for seasonal influenza in humans","volume":"12","author":"Nakaya HI","year":"2011","unstructured":"HI Nakaya, , Systems biology of vaccination for seasonal influenza in humans. Nat Immunol 12, 786\u2013795 (2011).","journal-title":"Nat Immunol"},{"key":"e_1_3_4_26_2","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1084\/jem.20082292","article-title":"Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses","volume":"205","author":"Gaucher D","year":"2008","unstructured":"D Gaucher, , Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med 205, 3119\u20133131 (2008).","journal-title":"J Exp Med"},{"key":"e_1_3_4_27_2","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature09907","article-title":"A diverse range of gene products are effectors of the type I interferon antiviral response","volume":"472","author":"Schoggins JW","year":"2011","unstructured":"JW Schoggins, , A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472, 481\u2013485 (2011).","journal-title":"Nature"},{"key":"e_1_3_4_28_2","first-page":"E3503","article-title":"Merck Ad5\/HIV induces broad innate immune activation that predicts CD8+ T-cell responses but is attenuated by preexisting Ad5 immunity","volume":"109","author":"Zak DE","year":"2012","unstructured":"DE Zak, , Merck Ad5\/HIV induces broad innate immune activation that predicts CD8+ T-cell responses but is attenuated by preexisting Ad5 immunity. Proc Natl Acad Sci USA 109, E3503\u2013E3512 (2012).","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_4_29_2","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/ni.2789","article-title":"Molecular signatures of antibody responses derived from a systems biology study of five human vaccines","volume":"15","author":"Li S","year":"2014","unstructured":"S Li, , Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. Nat Immunol 15, 195\u2013204 (2014).","journal-title":"Nat Immunol"},{"key":"e_1_3_4_30_2","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/nature06890","article-title":"Rapid cloning of high-affinity human monoclonal antibodies against influenza virus","volume":"453","author":"Wrammert J","year":"2008","unstructured":"J Wrammert, , Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453, 667\u2013671 (2008).","journal-title":"Nature"},{"key":"e_1_3_4_31_2","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s10439-007-9317-7","article-title":"Large-scale optimization-based classification models in medicine and biology","volume":"35","author":"Lee EK","year":"2007","unstructured":"EK Lee, Large-scale optimization-based classification models in medicine and biology. Ann Biomed Eng 35, 1095\u20131109 (2007).","journal-title":"Ann Biomed Eng"},{"key":"e_1_3_4_32_2","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1086\/650310","article-title":"Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine","volume":"201","author":"Vahey MT","year":"2010","unstructured":"MT Vahey, , Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine. J Infect Dis 201, 580\u2013589 (2010).","journal-title":"J Infect Dis"},{"key":"e_1_3_4_33_2","doi-asserted-by":"crossref","first-page":"6375","DOI":"10.1038\/ncomms7375","article-title":"Generation of cellular immune memory and B-cell immunity is impaired by natural killer cells","volume":"6","author":"Rydyznski C","year":"2015","unstructured":"C Rydyznski, , Generation of cellular immune memory and B-cell immunity is impaired by natural killer cells. Nat Commun 6, 6375 (2015).","journal-title":"Nat Commun"},{"key":"e_1_3_4_34_2","doi-asserted-by":"crossref","first-page":"e87463","DOI":"10.1371\/journal.pone.0087463","article-title":"Contribution of the Ly49E natural killer receptor in the immune response to Plasmodium berghei infection and control of hepatic parasite development","volume":"9","author":"Filtjens J","year":"2014","unstructured":"J Filtjens, , Contribution of the Ly49E natural killer receptor in the immune response to Plasmodium berghei infection and control of hepatic parasite development. PLoS One 9, e87463 (2014).","journal-title":"PLoS One"},{"key":"e_1_3_4_35_2","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.4049\/jimmunol.177.2.1229","article-title":"NK cell responses to Plasmodium infection and control of intrahepatic parasite development","volume":"177","author":"Roland J","year":"2006","unstructured":"J Roland, , NK cell responses to Plasmodium infection and control of intrahepatic parasite development. J Immunol 177, 1229\u20131239 (2006).","journal-title":"J Immunol"},{"key":"e_1_3_4_36_2","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1084\/jem.20011889","article-title":"Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines","volume":"195","author":"Gonzalez-Aseguinolaza G","year":"2002","unstructured":"G Gonzalez-Aseguinolaza, , Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines. J Exp Med 195, 617\u2013624 (2002).","journal-title":"J Exp Med"},{"key":"e_1_3_4_37_2","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian A","year":"2005","unstructured":"A Subramanian, , Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102, 15545\u201315550 (2005).","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_4_38_2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/cyto.a.21015","article-title":"SPICE: Exploration and analysis of post-cytometric complex multivariate datasets","volume":"79","author":"Roederer M","year":"2011","unstructured":"M Roederer, JL Nozzi, MC Nason, SPICE: Exploration and analysis of post-cytometric complex multivariate datasets. Cytometry A 79, 167\u2013174 (2011).","journal-title":"Cytometry A"}],"container-title":["Proceedings of the National Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.pnas.org\/syndication\/doi\/10.1073\/pnas.1621489114","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pnas.org\/doi\/pdf\/10.1073\/pnas.1621489114","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T12:43:41Z","timestamp":1654605821000},"score":1,"resource":{"primary":{"URL":"https:\/\/pnas.org\/doi\/full\/10.1073\/pnas.1621489114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,13]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,2,28]]}},"alternative-id":["10.1073\/pnas.1621489114"],"URL":"https:\/\/doi.org\/10.1073\/pnas.1621489114","relation":{},"ISSN":["0027-8424","1091-6490"],"issn-type":[{"value":"0027-8424","type":"print"},{"value":"1091-6490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,13]]},"assertion":[{"value":"2017-02-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}